Pharmaceuticals, Biotechnology and Life Sciences
By Pharmaceutical Daily Editorial Staff As the conflict in the Middle East enters its second month, the pharmaceutical industry across...
By Pharmaceutical Daily Editorial Staff As the conflict in the Middle East enters its second month, the pharmaceutical industry across Europe is confronting a reality that industry executives and policymakers...
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.
Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for a specific population of ischemic heart failure patients
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according...
In the past few months, the corporate world has seen a surge in workforce reductions that are explicitly tied to...
By Pharmaceutical Daily Editorial Staff As the conflict in the Middle East enters its second month, the pharmaceutical industry across…
BioPharma Credit deploys another $125 million into a pre-approval biotech. But the company it just backed is the one whose stock fell more than 50% on its Phase 3 data.
Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for a specific population of ischemic heart failure patients
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.
The Finnish biotech is going back to shareholders with a fully covered offering, aiming to fund a pivotal Phase II trial in high-risk myelodysplastic syndrome — and postponing its AGM for reasons that are anything but routine
A structural reorganization and a key appointment reveal a company that has moved beyond proving itself and is now building for dominance
The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon
An 80 million share rights offering authorized in Turku signals a company racing against its own runway
BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI
CEO of Leica Microsystems, a Danaher company — one of the few life sciences representatives in a room otherwise dominated by automotive and industrial giants.
